Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2019 1
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K, Eknert J, Öfverholm E, Papantoniou D, Jawdat F, Verbiéné I, Laurell A, Jänes E, Sandzén J, Wojtyna-Dziedzic E, Lagstam I, Söderkvist K, Costa Svedman F, Liedberg F, Bruzelius M, Fransson AS, Kjellström S, Omland LH, Pappot H, Ullén A. Holmsten K, et al. Among authors: fransson as. Clin Genitourin Cancer. 2023 Dec;21(6):e438-e448. doi: 10.1016/j.clgc.2023.05.008. Epub 2023 May 17. Clin Genitourin Cancer. 2023. PMID: 37308329 Free article.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinen MJ, Zeke M, Huttunen T, Ginman C; Investigators of the Scandinavian Prostate Cancer Study No. 13. Kellokumpu-Lehtinen PL, et al. Among authors: fransson as. Eur Urol. 2019 Dec;76(6):823-830. doi: 10.1016/j.eururo.2019.08.010. Epub 2019 Aug 20. Eur Urol. 2019. PMID: 31443961 Clinical Trial.
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial.
Kellokumpu-Lehtinen PL, Fransson AS, Marttila T, Lehtinen I, Huttunen T, Thellenberg-Karlsson C; SPCG-13 Investigators. Kellokumpu-Lehtinen PL, et al. Among authors: fransson as. Eur Urol Oncol. 2025 Aug;8(4):999-1002. doi: 10.1016/j.euo.2025.04.013. Epub 2025 Apr 30. Eur Urol Oncol. 2025. PMID: 40312180 Free article. Clinical Trial.
Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.
Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C; SPCG-13. Kellokumpu-Lehtinen PL, et al. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):303-7. doi: 10.1038/pcan.2012.13. Prostate Cancer Prostatic Dis. 2012. PMID: 22546837 Clinical Trial.